Truist analyst Richard Newitter lowered the firm’s price target on Inari Medical (NARI) to $52 from $61 and keeps a Hold rating on the shares. While the firm’s intra-quarter conversations with surgeons and companies suggests the market is likely growing fairly steadily at or even slightly above normal rates, Inari will likely continue to lose some additional share to Penumbra (PEN) in an expanding thrombectomy category, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
- Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry
- SHAREHOLDER ALERT: Potential Recovery for Inari Medical, Inc. (NARI) Investors
- Inari Medical price target lowered to $75 from $79 at Canaccord
- Inari Medical price target lowered to $86 from $93 at BTIG
- Piper Sandler downgrades Inari Medical to Neutral on core concerns, DOJ probe